Purpose: The high cardiovascular mortality in Peripheral Artery Disease (PAD) means secondary prevention needs accurate risk assessment and monitoring. The TEAM-PAD randomised trial compared reduction in cardiovascular risk in multidisciplinary team (MDT) care to usual care using the SMART-REACH score. We assessed 9-month outcomes and explored if treatment effects were also measurable using an Australian risk calculator (AusCVD). Methodology: The primary endpoint in the TEAM-PAD trial was change in cardiovascular risk from baseline to 9-months, assessed using SMART-REACH. AusCVD scores were analysed for exploratory comparison. Between group differences in risk change (MDT vs usual care) were assessed and predictors of improvement were evaluated by correlation and logistic regression. Results: A total of 130 patients were included (MDT n=66; standard care n=64). MDT significantly improved cardiovascular risk as measured by SMART-REACH, with a mean between group difference of 3.8 (p=0.018), but not as measured by AusCVD (p=0.457). Overall, there was no significant risk change across the cohort for either SMART-REACH (46.9 vs 48.2; p=0.066) or AusCVD (16.3 vs 17.4; p=0.152). SMART-REACH and AusCVD change scores were weakly correlated (ρ=0.084, p=0.348). SMART-REACH improvement was associated with higher baseline LDL (OR 1.7; p=0.014), while current smoking reduced likelihood of improvement (OR 0.3; p=0.025). Improvement in AusCVD measured risk was associated with CLTI (OR 2.5; p=0.03), weekly exercise (OR 2.7; p=0.02), and higher baseline SBP (OR 1.0; p=0.03). Conclusion: At 9-months, MDT care improved cardiovascular risk for PAD patients, as measured by SMART-REACH, and despite no overall cohort change, we demonstrated that risk can be modified with structured care. The absence of detectable change using AusCVD suggests differences in treatment sensitivity. Risk scores must support both risk stratification and monitoring, needing further validation in clinical use.